| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 32
| Issue : 3 | Page : 128-131 |
|
|
Optimizing anticancer therapy in newly diagnosed metastatic castration sensitive prostate cancer
Anastasios Thanos
Department of Urology, Ygeias Melathron Hospital, TYPET, Athens, Greece
Correspondence Address:
Anastasios Thanos
Department of Urology, Ygeias Melathron Hospital-TYPET, Therianou 4-6, Athens, PC:11473
Greece
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/HUAJ.HUAJ_19_20
|
|
|
Historically, androgen deprivation therapy has been the standard of care in the management of metastatic castration sensitive prostate cancer (mCSPC). However, during the past 5 years, numerous different treatment options have become available and have been set under investigation. The addition of docetaxel or abiraterone acetate has improved outcomes for patients with mCSPC and has become a new standard of care. New drugs targeting androgen receptor axis, local therapy including surgery, radiotherapy, and brachytherapy as well as metastatic-directed treatments have also demonstrated promising outcomes. In this work, the available data on all treatment modalities employed in mCSPC are being reviewed.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
